These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11330006)

  • 1. Data nail down the astounding cost of diabetes-related care.
    Capitation Rates Data; 2001 Apr; 6(4):42-5. PubMed ID: 11330006
    [No Abstract]   [Full Text] [Related]  

  • 2. Diabetes and obesity: the twin epidemics.
    Smyth S; Heron A
    Nat Med; 2006 Jan; 12(1):75-80. PubMed ID: 16397575
    [No Abstract]   [Full Text] [Related]  

  • 3. Diabetes and baby boomers.
    Nev Rnformation; 1998 May; 7(2):19-22. PubMed ID: 10614350
    [No Abstract]   [Full Text] [Related]  

  • 4. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
    Palmer AJ; Roze S; Valentine WJ; Minshall ME; Foos V; Lurati FM; Lammert M; Spinas GA
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S5-26. PubMed ID: 15324513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes management: current diagnostic criteria, drug therapies, and state legislation.
    Lyons T; Gourley G; Holt JM
    Am J Manag Care; 1997 Oct; 3(10):1599-608; quiz 1161-4. PubMed ID: 10178463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health care use and costs in the decade after identification of type 1 and type 2 diabetes: a population-based study.
    Johnson JA; Pohar SL; Majumdar SR
    Diabetes Care; 2006 Nov; 29(11):2403-8. PubMed ID: 17065675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Health economics analysis of diabetes is necessary. It facilitates decision-making and international comparison].
    Henriksson F; Agardh CD; Berne C; Bolinder J; Jönsson B
    Lakartidningen; 1999 Sep; 96(37):3915-6, 3919. PubMed ID: 10522101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges in funding diabetes care: a health economic perspective.
    Weber C
    Expert Rev Pharmacoecon Outcomes Res; 2010 Oct; 10(5):517-24. PubMed ID: 20950068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In response to article on CODEIRE study.
    Smith SM; O'Dowd T
    Ir Med J; 2007 Feb; 100(2):378-9. PubMed ID: 17436462
    [No Abstract]   [Full Text] [Related]  

  • 10. The cost of treating type 2 diabetes (CODEIRE).
    Nolan JJ; O'Halloran D; McKenna TJ; Firth R; Redmond S
    Ir Med J; 2006; 99(10):307-10. PubMed ID: 17274175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Juvenile obesity and comorbidity type 2 diabetes mellitus (T2 DM) in Germany: development and cost-of-illness analysis].
    Wolfenstetter SB
    Gesundheitswesen; 2006 Oct; 68(10):600-12. PubMed ID: 17099820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term consequences of type 2 diabetes mellitus: economic impact on society and managed care.
    Killilea T
    Am J Manag Care; 2002 Oct; 8(16 Suppl):S441-9. PubMed ID: 12408407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost effects.
    Nurs Times; 1998 Jun 3-9; 94(22):66. PubMed ID: 9687739
    [No Abstract]   [Full Text] [Related]  

  • 14. Healthcare charges and utilization associated with diabetic neuropathy: impact of Type 1 diabetes and presence of other diabetes-related complications and comorbidities.
    Zhao Y; Ye W; Boye KS; Holcombe JH; Swindle R
    Diabet Med; 2009 Jan; 26(1):61-9. PubMed ID: 19125762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the CORE Diabetes Model against epidemiological and clinical studies.
    Palmer AJ; Roze S; Valentine WJ; Minshall ME; Foos V; Lurati FM; Lammert M; Spinas GA
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S27-40. PubMed ID: 15324514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innovative approaches to reduce diabetes costs.
    Reese AB
    N C Med J; 2011; 72(5):409-12. PubMed ID: 22416528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The economic burden of nephropathy in diabetic patients in Germany in 2002.
    Happich M; Landgraf R; Piehlmeier W; Falkenstein P; Stamenitis S
    Diabetes Res Clin Pract; 2008 Apr; 80(1):34-9. PubMed ID: 18187227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economics of type 1 diabetes.
    Tao BT; Taylor DG
    Endocrinol Metab Clin North Am; 2010 Sep; 39(3):499-512. PubMed ID: 20723816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economics of type 2 diabetes prevention.
    Kissimova-Skarbek K
    Przegl Lek; 2006; 63 Suppl 4():9-11. PubMed ID: 16967708
    [No Abstract]   [Full Text] [Related]  

  • 20. The cost-effectiveness of intensive therapy for diabetes mellitus.
    Herman WH; Dasbach EJ; Songer TJ; Eastman RC
    Endocrinol Metab Clin North Am; 1997 Sep; 26(3):679-95. PubMed ID: 9314022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.